Ruoyu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ruoyu Wang has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
- Zhe Wang
Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
12 shared publications - Shanshan Liang
Affiliated Zhongshan Hospital of Dalian University Dalian China
10 shared publications Zhe Wang
Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University
10 shared publicationsYanhua Fang
The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China
7 shared publicationsChuanhao Zhang
Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, People’s Republic of China
6 shared publicationsJianing Jiang
Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University
4 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1892242
The prognostic value of lymphocyte-albumin-neutrophil ratio variability in patients with breast cancer undergoing radiotherapy
Background: Traditional static biomarkers often fail to capture the ongoing immune-nutritional trajectory of cancer patients. This study aimed to evaluate the prognostic relevance of dynamic variation in the Lymphocyte-Albumin-Neutrophil Ratio (LANR) in patients with operable breast cancer (BC), with exploratory analyses according to postoperative radiotherapy (RT) status. Methods: We retrospectively evaluated women with BC with operable invasive breast cancer. LANR variability was quantified using the coefficient of variation (CV) of the pre-operative and post-chemotherapy measurements to represent the magnitude of relative variability between the two time points. Patients were categorized into high and low LANR variability groups using a data-derived cutoff. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier curves and multivariable Cox proportional hazards models, including an exploratory interaction analysis according to postoperative radiotherapy (RT) status. Results: Among 1800 nonmetastatic BC women included in total, 8.2% (148/1800) death and 12% (216/1800) recurrence occurred after a median follow-up of 93 months (interquartile range, 73–116 months). In the overall cohort, the proportion of deaths was higher in the high-variability group (9.43% vs. 6.49%, P = 0.031), and the Kaplan–Meier comparison showed poorer OS (P = 0.032). In the fully adjusted model, the overall association was not statistically significant (HR = 1.34, 95% CI: 0.94–1.89, P = 0.11). The LANR variability-by-RT interaction was statistically significant for OS (P for interaction = 0.01) but not for PFS (P for interaction = 0.685). In the RT subgroup, high LANR variability was associated with poorer OS (HR = 1.82, 95% CI: 1.10–3.03, P = 0.02), whereas no clear association was observed in the non-RT subgroup (HR = 1.02, 95% CI: 0.63–1.66, P = 0.92). Conclusions: LANR variability is an inexpensive and readily available dynamic immune-nutritional indicator. A high LANR variability may help identify patients who require closer follow-up and monitoring, especially for those receiving postoperative radiotherapy. Further prospective validation and comparative analyses with established inflammatory and nutritional markers are required before clinical implementation.
- 3 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1892242
Open AccessThe prognostic value of lymphocyte-albumin-neutrophil ratio variability in patients with breast cancer undergoing radiotherapy
Background: Traditional static biomarkers often fail to capture the ongoing immune-nutritional trajectory of cancer patients. This study aimed to evaluate the prognostic relevance of dynamic variation in the Lymphocyte-Albumin-Neutrophil Ratio (LANR) in patients with operable breast cancer (BC), with exploratory analyses according to postoperative radiotherapy (RT) status. Methods: We retrospectively evaluated women with BC with operable invasive breast cancer. LANR variability was quantified using the coefficient of variation (CV) of the pre-operative and post-chemotherapy measurements to represent the magnitude of relative variability between the two time points. Patients were categorized into high and low LANR variability groups using a data-derived cutoff. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier curves and multivariable Cox proportional hazards models, including an exploratory interaction analysis according to postoperative radiotherapy (RT) status. Results: Among 1800 nonmetastatic BC women included in total, 8.2% (148/1800) death and 12% (216/1800) recurrence occurred after a median follow-up of 93 months (interquartile range, 73–116 months). In the overall cohort, the proportion of deaths was higher in the high-variability group (9.43% vs. 6.49%, P = 0.031), and the Kaplan–Meier comparison showed poorer OS (P = 0.032). In the fully adjusted model, the overall association was not statistically significant (HR = 1.34, 95% CI: 0.94–1.89, P = 0.11). The LANR variability-by-RT interaction was statistically significant for OS (P for interaction = 0.01) but not for PFS (P for interaction = 0.685). In the RT subgroup, high LANR variability was associated with poorer OS (HR = 1.82, 95% CI: 1.10–3.03, P = 0.02), whereas no clear association was observed in the non-RT subgroup (HR = 1.02, 95% CI: 0.63–1.66, P = 0.92). Conclusions: LANR variability is an inexpensive and readily available dynamic immune-nutritional indicator. A high LANR variability may help identify patients who require closer follow-up and monitoring, especially for those receiving postoperative radiotherapy. Further prospective validation and comparative analyses with established inflammatory and nutritional markers are required before clinical implementation.
- Open Access
- 1 June 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 883
Schisandrin B Exerts Radiosensitizing Effects on Breast Cancer via Dual Mechanisms of Cell Cycle/DNA Repair and Gut Microbiota-Immune Axis Modulation
Background/Objectives: Schisandrin B (Sch B), a bioactive lignan of Schisandra chinensis has been commonly investigated for its antitumor activities, yet its radiosensitizing effect and mechanism remain unclear. This study was conducted to investigate the radiosensitizing effects of Sch B in breast cancer (BC) and elucidate its molecular mechanisms, with a specific focus on the gut microbiota–immune axis. Methods: In vitro, CCK-8, colony formation, and 3D spheroid assays were used to evaluate the effects of Sch B on proliferation inhibition and radiosensitization, flow cytometry and immunofluorescence were used to elucidate the mechanisms involved. In vivo, 4T1 tumor-bearing mice were treated with Sch B, and 16S rDNA sequencing and LC-MS/MS were used to analyze the gut microbiota and short-chain fatty acid (SCFA) metabolism. IHC and qPCR detected antitumor immune responses. Results: Sch B inhibited the proliferation of BC cells in a time- and dose-dependent manner with negligible toxicity to the mammary epithelial cell line MCF-10A. Furthermore, Sch B enhanced the radiosensitivity (sensitization enhancement ratio: 1.20~1.77) of BC by inducing G1 phase cell cycle arrest and delaying radiation-induced DNA double-strand break repair. In vivo, Sch B suppressed BC growth in BALB/c mice without causing obvious systemic toxicity. Sch B reversed tumor-induced gut microbiota dysbiosis (restoring species abundance and the Firmicutes/Bacteroidetes ratio, enriching beneficial genera such as Lactobacillus and Butyrobacter) and normalized SCFA profiles (correlative evidence). Furthermore, Sch B modulated systemic immune responses by increasing the expression of Ifng, Cxcl10, Ddx58 and promoting CD3+ and CD8+ T-cell infiltration in tumors. Conclusions: Sch B exerts BC radiosensitization through dual mechanisms, direct regulation of the cell cycle and DNA repair, and indirect modulation of the gut microbiota-immune axis (correlative evidence), highlighting it as a safe and effective candidate for improving the efficacy of BC radiotherapy.
- 1 June 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 883
Open AccessSchisandrin B Exerts Radiosensitizing Effects on Breast Cancer via Dual Mechanisms of Cell Cycle/DNA Repair and Gut Microbiota-Immune Axis Modulation
Background/Objectives: Schisandrin B (Sch B), a bioactive lignan of Schisandra chinensis has been commonly investigated for its antitumor activities, yet its radiosensitizing effect and mechanism remain unclear. This study was conducted to investigate the radiosensitizing effects of Sch B in breast cancer (BC) and elucidate its molecular mechanisms, with a specific focus on the gut microbiota–immune axis. Methods: In vitro, CCK-8, colony formation, and 3D spheroid assays were used to evaluate the effects of Sch B on proliferation inhibition and radiosensitization, flow cytometry and immunofluorescence were used to elucidate the mechanisms involved. In vivo, 4T1 tumor-bearing mice were treated with Sch B, and 16S rDNA sequencing and LC-MS/MS were used to analyze the gut microbiota and short-chain fatty acid (SCFA) metabolism. IHC and qPCR detected antitumor immune responses. Results: Sch B inhibited the proliferation of BC cells in a time- and dose-dependent manner with negligible toxicity to the mammary epithelial cell line MCF-10A. Furthermore, Sch B enhanced the radiosensitivity (sensitization enhancement ratio: 1.20~1.77) of BC by inducing G1 phase cell cycle arrest and delaying radiation-induced DNA double-strand break repair. In vivo, Sch B suppressed BC growth in BALB/c mice without causing obvious systemic toxicity. Sch B reversed tumor-induced gut microbiota dysbiosis (restoring species abundance and the Firmicutes/Bacteroidetes ratio, enriching beneficial genera such as Lactobacillus and Butyrobacter) and normalized SCFA profiles (correlative evidence). Furthermore, Sch B modulated systemic immune responses by increasing the expression of Ifng, Cxcl10, Ddx58 and promoting CD3+ and CD8+ T-cell infiltration in tumors. Conclusions: Sch B exerts BC radiosensitization through dual mechanisms, direct regulation of the cell cycle and DNA repair, and indirect modulation of the gut microbiota-immune axis (correlative evidence), highlighting it as a safe and effective candidate for improving the efficacy of BC radiotherapy.
- 23 April 2026
- Published by Elsevier in Artificial Intelligence in Medicine
- Vol. 178, 103439
Topo-UNet: A topology-aware multi-task network for pulmonary vessel segmentation
- 23 April 2026
- Published by Elsevier in Artificial Intelligence in Medicine
- Vol. 178, 103439
Topo-UNet: A topology-aware multi-task network for pulmonary vessel segmentation
- Open Access
- 23 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1722115
Recent advances in preclinical studies combining hyperthermia therapy with novel immune checkpoint targeting agents
Hyperthermia has been used as an adjuvant therapy alongside radiotherapy and chemotherapy for cancer treatment in some countries. However, since the 2000s, growing evidence has indicated that hyperthermia exerts regulatory effects not only on cancer cells but also on stromal immune cells and the research interest in this topic has grown notably in the current “era of immunotherapy”. Of particular interest to oncoimmunologists and hyperthermia researchers, recent studies have shown that hyperthermia modulates the expression of a wide range of immune checkpoint and co-stimulatory molecules. In addition to the PD-1/PD-L1 and CTLA-4/CD80/CD86 checkpoints previously reported and intensively discussed in existing reviews, recent studies indicate that hyperthermia exerts a broader regulatory effect on many other checkpoint and co-stimulatory molecules, include TIGIT/CD155, Tim-3/Gal-9, OX40/OX40L, and 4-1BB/4-1BBL on T cells, CD47/SIRPα on macrophages, and CD40/CD40L on dendritic cells. The present review aims to provide a complementary update, focusing specifically on recent advances in understanding how hyperthermia regulates the expression of these newer targets, as well as preclinical evidence for combining hyperthermia with novel therapeutic agents targeting these molecules. The insights gained from these preclinical studies could serve as a valuable foundation for future experimental investigations and clinical translation.
- 23 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1722115
Open AccessRecent advances in preclinical studies combining hyperthermia therapy with novel immune checkpoint targeting agents
Hyperthermia has been used as an adjuvant therapy alongside radiotherapy and chemotherapy for cancer treatment in some countries. However, since the 2000s, growing evidence has indicated that hyperthermia exerts regulatory effects not only on cancer cells but also on stromal immune cells and the research interest in this topic has grown notably in the current “era of immunotherapy”. Of particular interest to oncoimmunologists and hyperthermia researchers, recent studies have shown that hyperthermia modulates the expression of a wide range of immune checkpoint and co-stimulatory molecules. In addition to the PD-1/PD-L1 and CTLA-4/CD80/CD86 checkpoints previously reported and intensively discussed in existing reviews, recent studies indicate that hyperthermia exerts a broader regulatory effect on many other checkpoint and co-stimulatory molecules, include TIGIT/CD155, Tim-3/Gal-9, OX40/OX40L, and 4-1BB/4-1BBL on T cells, CD47/SIRPα on macrophages, and CD40/CD40L on dendritic cells. The present review aims to provide a complementary update, focusing specifically on recent advances in understanding how hyperthermia regulates the expression of these newer targets, as well as preclinical evidence for combining hyperthermia with novel therapeutic agents targeting these molecules. The insights gained from these preclinical studies could serve as a valuable foundation for future experimental investigations and clinical translation.
- Open Access
- 28 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
miR-320a enhances radiosensitivity in non-small cell lung cancer by targeting RAD51 and modulating ferroptosis via GPX4
Radiotherapy is an essential treatment for non-small cell lung cancer (NSCLC), but its effectiveness is often reduced by radioresistance. miR-320a has been shown to improve radiosensitivity in NSCLC, but the molecular mechanisms are not well understood. This study investigates how miR-320a regulates RAD51 to affect the radiosensitivity of NSCLC. miR-320a expression in NSCLC tissues and cell lines was evaluated using The Cancer Genome Atlas (TCGA) data and qRT-PCR. RAD51 was predicted as a miR-320a target using bioinformatic tools (TargetScan, miRDB, miRTarBase) and validated by dual-luciferase reporter assays. Functional experiments were conducted to examine the effects of miR-320a and RAD51 manipulation on NSCLC cell responses to varying radiation doses. Ferroptosis was examined by measuring lipid reactive oxygen species (ROS) and GPX4 expression levels. miR-320a expression was markedly reduced in NSCLC tissues and cell lines relative to normal controls and showed a positive association with clinical radiosensitivity. Functional experiments demonstrated that miR-320a overexpression increased radiosensitivity by inhibiting post-irradiation cell proliferation, colony formation, and migration. RAD51 was validated as a direct post-transcriptional target of miR-320a. Mechanistically, RAD51 expression inversely correlated with miR-320a (R = −0.16, P < 0.001) and was associated with reduced radiosensitivity both in vitro and in patient samples. Importantly, RAD51 knockdown reversed the radioresistance induced by miR-320a inhibition. Further analyses revealed that RAD51 positively regulated GPX4 expression, thereby suppressing ferroptosis. Inhibition of RAD51 or restoration of miR-320a led to enhanced lipid peroxidation, as evidenced by increased lipid ROS accumulation and reduced GPX4 expression, ultimately sensitizing NSCLC cells to radiotherapy. Our results indicate that miR-320a promotes NSCLC radiosensitivity through a negative regulation of RAD51. The miR-320a/RAD51/GPX4 axis may be used as a key pathway in regulating NSCLC radiosensitivity.
- 28 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessmiR-320a enhances radiosensitivity in non-small cell lung cancer by targeting RAD51 and modulating ferroptosis via GPX4
Radiotherapy is an essential treatment for non-small cell lung cancer (NSCLC), but its effectiveness is often reduced by radioresistance. miR-320a has been shown to improve radiosensitivity in NSCLC, but the molecular mechanisms are not well understood. This study investigates how miR-320a regulates RAD51 to affect the radiosensitivity of NSCLC. miR-320a expression in NSCLC tissues and cell lines was evaluated using The Cancer Genome Atlas (TCGA) data and qRT-PCR. RAD51 was predicted as a miR-320a target using bioinformatic tools (TargetScan, miRDB, miRTarBase) and validated by dual-luciferase reporter assays. Functional experiments were conducted to examine the effects of miR-320a and RAD51 manipulation on NSCLC cell responses to varying radiation doses. Ferroptosis was examined by measuring lipid reactive oxygen species (ROS) and GPX4 expression levels. miR-320a expression was markedly reduced in NSCLC tissues and cell lines relative to normal controls and showed a positive association with clinical radiosensitivity. Functional experiments demonstrated that miR-320a overexpression increased radiosensitivity by inhibiting post-irradiation cell proliferation, colony formation, and migration. RAD51 was validated as a direct post-transcriptional target of miR-320a. Mechanistically, RAD51 expression inversely correlated with miR-320a (R = −0.16, P < 0.001) and was associated with reduced radiosensitivity both in vitro and in patient samples. Importantly, RAD51 knockdown reversed the radioresistance induced by miR-320a inhibition. Further analyses revealed that RAD51 positively regulated GPX4 expression, thereby suppressing ferroptosis. Inhibition of RAD51 or restoration of miR-320a led to enhanced lipid peroxidation, as evidenced by increased lipid ROS accumulation and reduced GPX4 expression, ultimately sensitizing NSCLC cells to radiotherapy. Our results indicate that miR-320a promotes NSCLC radiosensitivity through a negative regulation of RAD51. The miR-320a/RAD51/GPX4 axis may be used as a key pathway in regulating NSCLC radiosensitivity.
- 11 February 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (9) , 823-839
Upconversion mesoporous silica nanoparticles co-delivering celecoxib and rose bengal enable multimodal immunogenic and anti-angiogenic therapy for spinal metastasis of non-small cell lung cancer
Non-small cell lung cancer (NSCLC) with spinal metastasis represents a clinical challenge due to its aggressive nature, limited treatment options, and profound impact on patient quality of life. Here, we report the development of an innovative upconversion mesoporous silica nanoparticle (UCMS) platform co-loaded with celecoxib and rose bengal (UCMS@CXB/RB), engineered to synergistically combine photodynamic therapy (PDT) and cyclooxygenase-2 (COX-2) inhibition. Upon near-infrared (NIR) irradiation, UCMS@CXB/RB generated abundant reactive oxygen species, triggered immunogenic cell death, and significantly suppressed prostaglandin E2 signaling, leading to reduced angiogenesis and improved antitumor immunity. In vitro and in vivo studies confirmed that this nanoplatform effectively remodeled the tumor microenvironment, inhibited tumor growth, and alleviated cancer-induced spinal dysfunction. Single-cell multi-omics analysis further revealed dynamic crosstalk among immune cells, tumor cells, and endothelial populations, providing mechanistic insights into the multifaceted therapeutic effects of UCMS@CXB/RB. Our results underscore the clinical potential of integrating PDT with targeted COX-2 blockade to address the complex pathophysiology of NSCLC spinal metastasis. This study presents a promising minimally invasive therapeutic strategy with strong translational relevance for managing metastatic NSCLC and improving patient outcomes.
- 11 February 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (9) , 823-839
Upconversion mesoporous silica nanoparticles co-delivering celecoxib and rose bengal enable multimodal immunogenic and anti-angiogenic therapy for spinal metastasis of non-small cell lung cancer
Non-small cell lung cancer (NSCLC) with spinal metastasis represents a clinical challenge due to its aggressive nature, limited treatment options, and profound impact on patient quality of life. Here, we report the development of an innovative upconversion mesoporous silica nanoparticle (UCMS) platform co-loaded with celecoxib and rose bengal (UCMS@CXB/RB), engineered to synergistically combine photodynamic therapy (PDT) and cyclooxygenase-2 (COX-2) inhibition. Upon near-infrared (NIR) irradiation, UCMS@CXB/RB generated abundant reactive oxygen species, triggered immunogenic cell death, and significantly suppressed prostaglandin E2 signaling, leading to reduced angiogenesis and improved antitumor immunity. In vitro and in vivo studies confirmed that this nanoplatform effectively remodeled the tumor microenvironment, inhibited tumor growth, and alleviated cancer-induced spinal dysfunction. Single-cell multi-omics analysis further revealed dynamic crosstalk among immune cells, tumor cells, and endothelial populations, providing mechanistic insights into the multifaceted therapeutic effects of UCMS@CXB/RB. Our results underscore the clinical potential of integrating PDT with targeted COX-2 blockade to address the complex pathophysiology of NSCLC spinal metastasis. This study presents a promising minimally invasive therapeutic strategy with strong translational relevance for managing metastatic NSCLC and improving patient outcomes.
- 12 January 2026
- Published by Wiley in Head & Neck
- Vol. 48 (6) , 1537-1546
Age‐Related Risk Stratification in HPV ‐Positive Oropharyngeal Cancer: Implications for Treatment De‐Intensification
Background: Although the AJCC eighth edition staging system incorporates HPV status, it remains insufficient to guide personalized treatment in HPV‐positive oropharyngeal cancer (OPC). This study aimed to identify the optimal age threshold and evaluate its association with overall survival (OS) to improve risk stratification and inform individualized treatment strategies. Methods: Data were extracted from the SEER database (2018–2021), the University Health Network (UHN), University of Toronto, and the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (NCC). Only HPV‐positive OPC cases with complete survival records were included. The optimal age threshold was identified using restricted cubic spline modeling in combination with a recursive partitioning approach. Prognostic factors beyond HPV status and AJCC eighth edition stage were evaluated using multivariable Cox proportional hazards models. Recursive partitioning analysis (RPA) was used to construct a risk stratification model. The primary endpoint was OS. Results: Of the 10 283 eligible patients (87.9% male; median age, 62 years), 2.7% had distant metastases at diagnosis. Restricted cubic spline analysis revealed that 62 years of age represents an important critical threshold. Multivariable Cox analysis revealed that patients younger than 62 years exhibited significantly improved OS (HR, 0.61; 95% CI, 0.54–0.70; p < 0.001). RPA stratified patients into five risk groups with distinct 2‐year OS: extremely low (96.8%), low (93.7%), intermediate (86.1%), high (74.6%), and extremely high risk (47.5%). Among patients classified in the extremely low‐risk group (T0‐2N0‐1M0 and younger than 62 years), no significant difference in OS was observed between those treated with radiotherapy alone and those treated with chemoradiotherapy. External validation in the UHN ( N = 843) and NCC ( N = 167) cohorts suggested that extremely low‐risk patients might be spared concurrent chemotherapy. Conclusions: This study developed a risk stratification model for patients with p16‐positive OPC based on the AJCC eighth edition staging and age. Patients in the extremely low‐risk group may derive limited benefit from concurrent chemotherapy, suggesting that its omission could be considered in selected patients and may help guide the design of future de‐escalation trials.
- 12 January 2026
- Published by Wiley in Head & Neck
- Vol. 48 (6) , 1537-1546
Age‐Related Risk Stratification in HPV ‐Positive Oropharyngeal Cancer: Implications for Treatment De‐Intensification
Background: Although the AJCC eighth edition staging system incorporates HPV status, it remains insufficient to guide personalized treatment in HPV‐positive oropharyngeal cancer (OPC). This study aimed to identify the optimal age threshold and evaluate its association with overall survival (OS) to improve risk stratification and inform individualized treatment strategies. Methods: Data were extracted from the SEER database (2018–2021), the University Health Network (UHN), University of Toronto, and the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (NCC). Only HPV‐positive OPC cases with complete survival records were included. The optimal age threshold was identified using restricted cubic spline modeling in combination with a recursive partitioning approach. Prognostic factors beyond HPV status and AJCC eighth edition stage were evaluated using multivariable Cox proportional hazards models. Recursive partitioning analysis (RPA) was used to construct a risk stratification model. The primary endpoint was OS. Results: Of the 10 283 eligible patients (87.9% male; median age, 62 years), 2.7% had distant metastases at diagnosis. Restricted cubic spline analysis revealed that 62 years of age represents an important critical threshold. Multivariable Cox analysis revealed that patients younger than 62 years exhibited significantly improved OS (HR, 0.61; 95% CI, 0.54–0.70; p < 0.001). RPA stratified patients into five risk groups with distinct 2‐year OS: extremely low (96.8%), low (93.7%), intermediate (86.1%), high (74.6%), and extremely high risk (47.5%). Among patients classified in the extremely low‐risk group (T0‐2N0‐1M0 and younger than 62 years), no significant difference in OS was observed between those treated with radiotherapy alone and those treated with chemoradiotherapy. External validation in the UHN ( N = 843) and NCC ( N = 167) cohorts suggested that extremely low‐risk patients might be spared concurrent chemotherapy. Conclusions: This study developed a risk stratification model for patients with p16‐positive OPC based on the AJCC eighth edition staging and age. Patients in the extremely low‐risk group may derive limited benefit from concurrent chemotherapy, suggesting that its omission could be considered in selected patients and may help guide the design of future de‐escalation trials.
- Open Access
- 16 December 2025
- Published by Taylor & Francis in OncoImmunology
- Vol. 14 (1) , 2602216
Mild microwave hyperthermia promotes mitotic catastrophe, induces time-delayed cGAS-STING activation and restores sensitivity to anti-PDL1 therapy in Pan02 pancreatic cancer model
Pancreatic ductal adenocarcinoma (PDAC) responds poorly to immune checkpoint inhibitors (ICIs), representingindicating an unmet clinical need. Hyperthermia therapy, an approved anti-cancer approach with limited adverse effects, has been suggested to be capable of modulating the tumor microenvironment (TiME). This study examined the potential of microwave hyperthermia (Ht) to restructure the TiME of Pan02 PDAC model and restore Pan02 tumor's sensitivity to ICIs, followed by mechanistic investigation. In vitro experiments were performed using a 41 °C water bath, and in vivo studies established the Pan02 murine model treated with 41 °C microwave hyperthermia + /- αPD-L1 therapy. In Ht-treated cells, increased percentages of nucleus envelope blebbing, micronucleation, and multi-/macro-nucleation were observed, and live imaging studies suggested mitotic catastrophe. Ht induced cGAS-STING activation, γH2AX formation, dsDNA release, and genomic damage (comet assay) in a time-delayed fashion 24-48 h after Ht. In the Pan02 model, the Ht and αPD-L1 combination significantly repressed the growth of Ht-treated and abscopal tumors and prolonged mouse survival. The TiME was significantly altered after Ht, featuring upregulated infiltration and maturation of DCs, CD8 + T cells, M1 macrophages, and activated cGAS-STING-IFN signaling. The addition of a STING antagonist abolished this tumor-suppressive effect. SUMO1 expression was significantly repressed after Ht, whereas SUMO1 overexpression attenuated Ht-induced cGAS-STING activation. The effect of Ht has also been validated in certain human PDAC cell lines. Taken together, our study suggests that microwave hyperthermia could be an excellent therapeutic companion of ICIs for PDAC management, associated with a novel mechanism of Ht-induced time-delayed DNA damage and STING activation.
- 16 December 2025
- Published by Taylor & Francis in OncoImmunology
- Vol. 14 (1) , 2602216
Open AccessMild microwave hyperthermia promotes mitotic catastrophe, induces time-delayed cGAS-STING activation and restores sensitivity to anti-PDL1 therapy in Pan02 pancreatic cancer model
Pancreatic ductal adenocarcinoma (PDAC) responds poorly to immune checkpoint inhibitors (ICIs), representingindicating an unmet clinical need. Hyperthermia therapy, an approved anti-cancer approach with limited adverse effects, has been suggested to be capable of modulating the tumor microenvironment (TiME). This study examined the potential of microwave hyperthermia (Ht) to restructure the TiME of Pan02 PDAC model and restore Pan02 tumor's sensitivity to ICIs, followed by mechanistic investigation. In vitro experiments were performed using a 41 °C water bath, and in vivo studies established the Pan02 murine model treated with 41 °C microwave hyperthermia + /- αPD-L1 therapy. In Ht-treated cells, increased percentages of nucleus envelope blebbing, micronucleation, and multi-/macro-nucleation were observed, and live imaging studies suggested mitotic catastrophe. Ht induced cGAS-STING activation, γH2AX formation, dsDNA release, and genomic damage (comet assay) in a time-delayed fashion 24-48 h after Ht. In the Pan02 model, the Ht and αPD-L1 combination significantly repressed the growth of Ht-treated and abscopal tumors and prolonged mouse survival. The TiME was significantly altered after Ht, featuring upregulated infiltration and maturation of DCs, CD8 + T cells, M1 macrophages, and activated cGAS-STING-IFN signaling. The addition of a STING antagonist abolished this tumor-suppressive effect. SUMO1 expression was significantly repressed after Ht, whereas SUMO1 overexpression attenuated Ht-induced cGAS-STING activation. The effect of Ht has also been validated in certain human PDAC cell lines. Taken together, our study suggests that microwave hyperthermia could be an excellent therapeutic companion of ICIs for PDAC management, associated with a novel mechanism of Ht-induced time-delayed DNA damage and STING activation.
- 14 October 2025
- Published by Springer Nature in Medical & Biological Engineering & Computing
- Vol. 64 (2) , 435-447
An ODE-based multi-resolution parallel network for respiratory motion estimation
During puncture procedures, respiratory motion can cause significant displacement of lesions. Fast and accurate estimation of pulmonary respiratory motion
- 14 October 2025
- Published by Springer Nature in Medical & Biological Engineering & Computing
- Vol. 64 (2) , 435-447
An ODE-based multi-resolution parallel network for respiratory motion estimation
During puncture procedures, respiratory motion can cause significant displacement of lesions. Fast and accurate estimation of pulmonary respiratory motion
- 24 September 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 70, 119-128
Serum creatinine and cystatin C-based index is a prognostic factor in patients with nonmetastatic breast cancer after surgery
- 24 September 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 70, 119-128
Serum creatinine and cystatin C-based index is a prognostic factor in patients with nonmetastatic breast cancer after surgery